BTX - BioTime, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
1.0700
-0.0400 (-3.60%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.1100
Open1.1300
Bid0.0000 x 900
Ask0.0000 x 1400
Day's Range1.0600 - 1.1100
52 Week Range0.6600 - 2.8100
Volume291,585
Avg. Volume588,175
Market Cap160.118M
Beta (3Y Monthly)3.45
PE Ratio (TTM)2.42
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire29 days ago

    BioTime Announces Appointment of General Counsel

    BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, today announced that it has appointed Chase C. Leavitt as BioTime’s General Counsel and Corporate Secretary. “We’re extremely fortunate to have Chase join us and bring his extensive public company experience as well as a strong track record to the role of general counsel,” stated Brian M. Culley, Chief Executive Officer of BioTime.

  • Business Wirelast month

    BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen®

    BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, has been awarded a new research & development grant for 2019 of up to 9 million Israeli New Shekels (approximately $2.5 million USD) from the Israel Innovation Authority (the “IIA”). The grant provides funding for the continued development of OpRegen®, the Company’s retinal pigment epithelium transplant therapy currently in Phase I/IIa development for the treatment of dry age-related macular degeneration, the leading cause of blindness in the developed world. To date, the IIA has provided annual grants totaling approximately $15 million for the development of the OpRegen program.

  • Business Wirelast month

    BioTime Reports First Quarter 2019 Financial Results and Provides Business Update

    ALAMEDA, Calif.-- -- Positive OpRegen ® Data Presented at Association for Research in Vision and Ophthalmology Annual Meeting Announced Issuance of New Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury Entered Into Exclusive Collaboration with Orbit Biomedical Ltd. BioTime, Inc. , a clinical-stage biotechnology company developing cellular therapies for unmet medical ...

  • Business Wirelast month

    BioTime Announces Issuance of U.S. Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury

    BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet needs, announced today the issuance of a Notice of Allowance for a patent from the United States Patent and Trademark Office (USPTO) for United States Patent Application No. 15/156,316 for a method of reducing spinal cord injury (SCI)-induced parenchymal cavitation in patients that have suffered an acute spinal cord injury. The claimed method involves injecting oligodendrocyte progenitor cells (OPCs) derived from human pluripotent stem cells into the SCI site and covers both human embryonic and induced pluripotent stem cell-derived OPCs. “We believe OPC1 acts via several distinct mechanisms to aid the recovery of SCI patients, one of which is the prevention or reduction of cavitation, and we are pleased at having received an allowance on this important patent, which we believe further enhances our OPC1 cell therapy program,” stated Brian M. Culley, Chief Executive Officer of BioTime.

  • Business Wire2 months ago

    BioTime to Report First Quarter 2019 Financial Results and Provide Business Update on May 9, 2019

    BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, today announced that it will report its first quarter 2019 financial and operating results on Thursday, May 9th, 2019, following the close of the U.S. financial markets. BioTime management will also host a conference call and webcast on Thursday, May 9th, 2019, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2019 financial results and to provide a business update. Interested parties may access the conference call by dialing (866) 888-8633 from the U.S. and Canada and (636) 812-6629 from elsewhere outside the U.S. and should request the “BioTime Inc. Call”.

  • Business Wire2 months ago

    BioTime Presents Updated Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting

    BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, announced that updated results from a Phase I/IIa clinical study of its lead product candidate, OpRegen®, a retinal pigment epithelium (RPE) cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA), will be presented today at the 2019 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019) in Vancouver, BC, Canada. Data from the study demonstrate that treatment with OpRegen continues to be well tolerated and in some patients, signs of structural improvement in the treated areas of the retina have been observed.

  • Business Wire2 months ago

    BioTime to Present SCiStar Clinical Study Top-Line Data at the 26th Annual American Society for Neural Therapy and Repair Conference

    BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, announced today that Edward D. Wirth, III, M.D., Ph.D., Chief Medical Officer of BioTime, will present at the 26th Annual American Society for Neural Therapy and Repair (ASNTR) Annual Conference on April 26th, 2019 at 10:30am EDT as part of Session 6: “Spinal Cord Injury”. Dr. Wirth’s presentation is entitled “Top-line 12-month Results from the SCiStar Study - A Phase 1/2a Trial of Human Embryonic Stem Cell-Derived Oligodendrocyte Progenitor Cells (OPC1) in Patients with Subacute Cervical Spinal Cord Injury”. “We believe the primary goals of the SCiStar Study, which were to observe the safety of OPC1 in cervical spinal cord injury patients as well as other important metrics including related to the optimal timing of OPC1 injection, tolerability of the immunosuppression regimen, engraftment of OPC1 cells, and rates of motor recovery observed among different study subpopulations, have all been successfully achieved,” stated Dr. Wirth.

  • Business Wire2 months ago

    BioTime to Present Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019)

    BioTime, Inc. , a clinical-stage biotechnology company developing new cellular therapies, announced today that updated results from a Phase I/IIa clinical study of its lead product candidate, OpRegen®, a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration with geographic atrophy, will be presented at the 2019 Association ...

  • Business Wire3 months ago

    BioTime to Present at Oppenheimer & Co. 29th Annual Healthcare Conference on March 20, 2019

    BioTime, Inc. , a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M. Culley, Chief Executive Officer, will be presenting at the Oppenheimer & Co.

  • Business Wire3 months ago

    BioTime Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

    ALAMEDA, Calif.-- -- Completed Acquisition of Asterias Biotherapeutics, Inc. Completed Distribution of AgeX Therapeutics Shares to BioTime Shareholders Entered Into Exclusive Collaboration with Orbit Biomedical Ltd. BioTime, Inc. , a clinical-stage biotechnology company focused on degenerative diseases, reported financial and operating results for the fourth quarter and full year ended December 31, ...

  • Business Wire3 months ago

    BioTime Announces Closing of Acquisition of Asterias Biotherapeutics Creating Leading Cell Therapy Company

    BioTime, Inc. (NYSE American and TASE: BTX), today announced the closing of its previously reported acquisition of Asterias Biotherapeutics, Inc. (Asterias), whereby BioTime has acquired through a merger, all of the remaining outstanding common stock of Asterias which was not previously owned by BioTime. As a result of the acquisition, Asterias became a wholly-owned subsidiary of BioTime and the operations of BioTime and Asterias have combined. Notably, 98% of BioTime votes cast and 96% of Asterias votes cast were in favor of the merger.

  • Business Wire3 months ago

    BioTime to Report Fourth Quarter and Full Year 2018 Financial Results on March 14th, 2019

    BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will report its fourth quarter and full year 2018 financial and operating results on Thursday, March 14th, 2019, following the close of the U.S. financial markets. BioTime management will also host a conference call and webcast on Thursday, March 14th, 2019, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2018 financial results and to provide a business update. Interested parties may access the conference call by dialing (866) 888-8633 from the U.S. and Canada and (636) 812-6629 from elsewhere outside the U.S. and should request the “BioTime Inc. Call”.

  • Business Wire4 months ago

    BioTime to Present at the 14Th Annual Scientific Meeting of the Association for Ocular Pharmacology and Therapeutics (AOPT 2019) on March 10, 2019

    BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced today that Francois Binette, PhD, Senior Vice President and Global Head of Product Development at BioTime, Inc., will present the 14th Annual Scientific Meeting of the Association For Ocular Pharmacology and Therapeutics (AOPT 2019) on March 10, 2019 at 1pm EDT, as part of Session 12: “Disruptive Technologies: Ophthalmic Tools and Methods That Have Changed The Ways We See The Eye”. AOPT 2019 will be held March 7-10.

  • GlobeNewswire4 months ago

    BioTime to Present New Data From OpRegen® and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019)

    ALAMEDA, Calif., Feb. 26, 2019 -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced today that updated.

  • GlobeNewswire4 months ago

    Consolidated Research: 2019 Summary Expectations for Walmart, W.R. Grace, BioTime, Genesee & Wyoming, Northrop Grumman, and Versum Materials — Fundamental Analysis, Key Performance Indications

    NEW YORK, Feb. 22, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire4 months ago

    BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias

    BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today provided a business update which included information on AgeX Therapeutics, Inc. (AgeX) (NYSE American: AGE) and BioTime’s two affiliated companies, OncoCyte Corporation (OncoCyte) (NYSE American: OCX), and Asterias Biotherapeutics, Inc. (Asterias) (NYSE American: AST). “In the past five months, BioTime has made rapid progress toward its commitment to become a leading cell therapy company by focusing on clinical-stage cell therapy product candidates with promising human data and supporting their development in part through targeted transactions among its affiliated companies,” stated Brian M. Culley, Chief Executive Officer of BioTime, Inc.

  • ACCESSWIRE4 months ago

    Most Intriguing Companies on the New LD Micro Index

    HENDERSON, NV / ACCESSWIRE / February 5, 2019 / Friday, LD Micro reinstituted their nearly 1000 company index of micro-caps, with the belief that our industry needs a truly accurate indicator of what is ...

  • GlobeNewswire5 months ago

    BioTime Inc. Affiliate Company OncoCyte Corporation Reports Successful Results With DetermaVu™ Diagnostic Test for Lung Cancer

    BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its affiliate company, OncoCyte Corporation (OncoCyte) (OCX), a developer of novel, non-invasive tests for the early detection of cancer, has reported positive results from an R&D validation study of DetermaVu™, a non-invasive, liquid biopsy test intended to facilitate clinical decision making in lung cancer diagnosis. As outlined in OncoCyte’s announcement, the R&D validation study demonstrated a sensitivity of 90% (95% CI 82%-95%) and specificity of 75% (95% CI 68%-81%) of DetermaVu™ on a prospectively collected cohort of 250 patient blood samples that were blinded to laboratory operators.

  • ACCESSWIRE5 months ago

    Today's Research Reports on Trending Tickers: BioTime and Zynerba Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / January 30, 2019 / U.S. markets were mostly down Tuesday on the latest batch of corporate earnings and as investors await details from the Feds' two-day policy meeting. The ...

  • Business Wire5 months ago

    AgeX Therapeutics Publishes Data in Peer-Reviewed Journal to Advance Potential Cell Therapy AgeX-BAT1 for Type II Diabetes and Obesity

    ALAMEDA, Calif.-- -- 30M U.S. adults suffer from diabetes and 93M from obesity, with associated medical costs of over $300B annually, necessitating an urgent need for novel treatments AgeX-BAT1 for Type II diabetes and obesity aims to return brown adipose tissue, also known as “brown” or “good” fat, back to levels found in young adults Loss of brown fat as a result of aging is associated with obesity ...

  • GlobeNewswire5 months ago

    BioTime Enters Into Exclusive Agreement With Orbit Biomedical Ltd. to Access Innovative Device for the Sub-Retinal Delivery of OpRegen® Cells for the Treatment of Dry-AMD

    Traditionally, the sub-retinal space is accessed via vitrectomy (removal of the vitreous, the gel-like substance that fills the eye), followed by an injection into the eye and through the retina. Orbit Biomedical’s injection system is designed to precisely and consistently deliver therapeutics to the sub-retinal space via a suprachoroidal route, avoiding the need for a vitrectomy and perforation of the retina. “Orbit Biomedical’s specifically-designed device offers surgeons an innovative solution for the delivery of therapies to the sub-retinal space, a well-known challenge in ophthalmology,” stated Brian M. Culley, Chief Executive Officer of BioTime.

  • GlobeNewswire5 months ago

    BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech Showcase

    BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced the appointment of Brandi L. Roberts, M.B.A. as Chief Financial Officer and Senior Vice President, Finance, effective January 7, 2019. "I’m excited to welcome Brandi to the BioTime team during this critical period in which we increase the focus on our clinical-stage product candidates and improve our business structure through recently-announced and pending transactions involving our affiliated companies, AgeX (NYSE American: AGE) and Asterias (NYSE American: AST),” stated Brian M. Culley, Chief Executive Officer of BioTime.

  • Business Wire6 months ago

    BioTime to Present at 2019 Biotech Showcase Investor Conference on January 7, 2019

    BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M. Culley, Chief Executive Officer of BioTime will be presenting at the 2019 Biotech Showcase Investor Conference on January 7th, 2019 at 9am Pacific Time at the Hilton San Francisco Union Square Hotel in the Franciscan A Ballroom in San Francisco, CA. “Our vision is to build BioTime into the premiere cell therapy company, pioneering whole-cell transplants to address unmet medical conditions such as macular degeneration and spinal cord injury1, which have not yielded to small molecule approaches,” stated Brian M. Culley, Chief Executive Officer of BioTime. “Awareness of our mission is vital and our presentation at Biotech Showcase is one of our first opportunities to share our updated plans with a broad audience and build support for BioTime’s short- and long-term objectives.

  • Business Wire6 months ago

    AgeX Therapeutics to Present at Biotech Showcase 2019

    AgeX Therapeutics, Inc. , a biotechnology company focused on developing and commercializing innovative therapeutics for human aging, today announced that it will present at Biotech Showcase, to be held January 7-9, 2019 in San Francisco, California.

  • Business Wire7 months ago

    BioTime Announces Publication of Positive Preclinical Results Utilizing Proprietary HyStem® Platform in Ischemic Stroke

    BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced the publication of positive preclinical results which demonstrate that targeted intracerebral delivery of brain-derived neurotrophic factor utilizing HyStem®, BioTime’s proprietary hydrogel delivery platform technology, may mitigate ischemic brain injury and restore functional benefits by reducing neuroinflammation. The article entitled, “Intracerebral Delivery of Brain-Derived Neurotrophic Factor Using HyStem®-C Hydrogel Implants Improves Functional Recovery and Reduces Neuroinflammation in a Rat Model of Ischemic Stroke,” was published in the International Journal of Molecular Sciences and is authored by clinicians at the Stanford University School of Medicine, Department of Neurosurgery.